ARS Pharmaceuticals (SPRY) Equity Ratio: 2021-2025
Historic Equity Ratio for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to 0.40.
- ARS Pharmaceuticals' Equity Ratio fell 57.12% to 0.40 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.40, marking a year-over-year decrease of 57.12%. This contributed to the annual value of 0.73 for FY2024, which is 26.10% down from last year.
- ARS Pharmaceuticals' Equity Ratio amounted to 0.40 in Q3 2025, which was down 35.44% from 0.61 recorded in Q2 2025.
- ARS Pharmaceuticals' 5-year Equity Ratio high stood at 0.99 for Q4 2023, and its period low was -0.51 during Q4 2021.
- Its 3-year average for Equity Ratio is 0.84, with a median of 0.95 in 2023.
- As far as peak fluctuations go, ARS Pharmaceuticals' Equity Ratio spiked by 290.54% in 2022, and later slumped by 57.12% in 2025.
- Over the past 5 years, ARS Pharmaceuticals' Equity Ratio (Quarterly) stood at -0.51 in 2021, then surged by 290.54% to 0.97 in 2022, then grew by 2.06% to 0.99 in 2023, then declined by 26.10% to 0.73 in 2024, then slumped by 57.12% to 0.40 in 2025.
- Its Equity Ratio stands at 0.40 for Q3 2025, versus 0.61 for Q2 2025 and 0.70 for Q1 2025.